PKM and renal cell carcinoma: To definitively demonstrate PKM2 stabilization, through escaping acetylation- and lysosomal-mediated degradation, drives drug-resistance in RCC cells, we generated an acetylation mutant of PKM2 by mutating lysine 305 (the PCAF-acetylation site) to arginine (K305R) (PKM2K305R) as described by Lv et al.34.